PEPTIDE COMPARISON

Tesamorelin vs Semaglutide

A narrow HIV-lipodystrophy medicine compared with product-specific metabolic indications.

QUICK ANSWER

Tesamorelin vs Semaglutide: the main difference.

Tesamorelin and semaglutide address different populations through different mechanisms. Their evidence should not be ranked as if both were general visceral-fat products.

Decision field	Tesamorelin	Semaglutide
Primary population	Adults with HIV and lipodystrophy	Product-specific diabetes, chronic weight-management, and other labeled populations
Mechanism	GHRH analog	GLP-1 receptor agonist
FDA status	Approved for reducing excess abdominal fat in one narrow population	Approved branded products with indication-specific labels
Visceral-fat context	Direct indication-specific evidence in HIV lipodystrophy	Body-weight and metabolic outcomes do not answer the same population-specific question
Main boundary	Not indicated for general weight-loss management	Approval does not transfer to every compounded or counterfeit product

SOURCES

Tesamorelin vs Semaglutide sources.

FDA / 2025EGRIFTA WR prescribing informationU.S. FDA Human trial / 2010Pooled analysis of two Phase 3 tesamorelin trialsPubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2026Wegovy application and labeling recordU.S. FDA FDA / 2026FDA concerns with unapproved GLP-1 drugsU.S. FDA

Tesamorelin vs Semaglutide: the main difference.

Tesamorelin vs Semaglutide sources.

Questions related to Tesamorelin vs Semaglutide.

Compare the next decision.